Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis
Tom Parks, Clare Wilson, Nigel Curtis, Anna Norrby-Teglund, Shiranee Sriskandan
CLINICAL INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2018
We evaluated the effect of intravenous immunoglobulin (IVIG) on mortality in clindamycin-treated streptococcal toxic shock syndrome using a meta-analysis. In association with IVIG, mortality fell from 33.7% to 15.7% with remarkable consistency across the single randomized and four nonrandomized studies.
Awarded by Medical Research Council
Awarded by National Institute for Health Research
Awarded by Public Health England
This work was supported by the Medical Research Council (grant G1100449 to T.P.), the National Institute for Health Research (grant ACF-2016-20-001 to T.P.), the National Institute for Health Research Health Protection Research Unit in Antimicrobial Resistance and Healthcare Associated Infection in partnership with Public Health England (grant HPRU-2012-10047), and the National Institute for Health Research Imperial Biomedical Research Centre.